In brief, metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk and the result were further confirmed through activating EGFR signaling using mEGF. The gene discussed is EGFR; the disease is urinary bladder carcinoma.